AIM ImmunoTech to Attend the 2025 Maxim Growth Summit

Rhea-AI Summary

AIM ImmunoTech (NYSE American: AIM) will participate at the 2025 Maxim Growth Summit in New York on October 22–23, 2025.

Company management will be available for in-person one-on-one meetings with qualified, registered investors, and the presentation slide deck is available on the company's Presentations page at aimimmuno.com. For the full summit agenda, visit the Maxim Growth Summit website.

OCALA, Fla., Oct. 20, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced it will participate at the 2025 Maxim Growth Summit, taking place October 22-23, 2025 in New York, NY. This prestigious event brings together industry leaders, innovators, and premier institutions to explore the latest trends and advancements across several industries.

As part of the conference, members of management will be available to participate in in-person one-on-one meetings with qualified members of the investor community who are registered to attend the conference. To view the Company’s Maxim Growth Summit presentation slide deck, please visit the Presentations page on aimimmuno.com.

For more information and a complete agenda of the Maxim Growth Summit, please visit www.maximgrp.com/2025-growth-summit.

About Maxim Group

Maxim Group LLC is a full-service investment banking, securities and wealth management firm headquartered in New York. The independent and employee-owned firm provides a full array of financial services including investment banking; private wealth management; and global institutional equity, fixed-income and derivatives sales & trading, equity research and prime brokerage services. Maxim Group LLC is a registered broker-dealer with the U.S. Securities and Exchange Commission (SEC) and the Municipal Securities Rulemaking Board (MSRB) and is a member of FINRA, SIPC, and NASDAQ. To learn more about Maxim Group LLC, visit maximgrp.com.

About AIM ImmunoTech Inc.

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen^® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials. Ampligen is currently being studied in collaboration with AstraZeneca in Phase 2 of a clinical trial combining AIM’s drug with durvalumab for the treatment of metastatic pancreatic cancer.

For more information, please visit aimimmuno.com and connect with the Company on X, LinkedIn, and Facebook.

Investor Contact:

JTC Team, LLC
Jenene Thomas
908.824.0775
AIM@jtcir.com

FAQ

When will AIM ImmunoTech present at the 2025 Maxim Growth Summit?

AIM will participate in the summit on October 22–23, 2025 in New York.

How can investors meet AIM ImmunoTech management at the Maxim Growth Summit?

Qualified, registered investors can request in-person one-on-one meetings with AIM management during the conference.

Where can I find AIM ImmunoTech's Maxim Growth Summit slide deck (AIM)?

The presentation slide deck is available on AIM ImmunoTech's Presentations page at aimimmuno.com.

Does AIM ImmunoTech require registration to meet management at the 2025 Maxim Growth Summit?

Yes. Meetings are available to qualified members of the investor community who are registered to attend the conference.

What are the dates and location for the 2025 Maxim Growth Summit where AIM (AIM) will appear?

The summit runs October 22–23, 2025 in New York, NY.

Where can I view the full agenda for the 2025 Maxim Growth Summit?

The complete summit agenda is available at www.maximgrp.com/2025-growth-summit.